🇺🇸 Fortaz in United States

FDA authorised Fortaz on 19 July 1985

Marketing authorisations

FDA — authorised 19 July 1985

  • Application: NDA050578
  • Marketing authorisation holder: PAI HOLDINGS PHARM
  • Local brand name: FORTAZ
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 November 1985

  • Application: ANDA062640
  • Marketing authorisation holder: ACS DOBFAR
  • Local brand name: CEFTAZIDIME
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 20 November 1985

  • Application: ANDA062655
  • Marketing authorisation holder: LILLY
  • Local brand name: TAZIDIME
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 10 July 1986

  • Application: ANDA062739
  • Marketing authorisation holder: LILLY
  • Local brand name: TAZIDIME IN PLASTIC CONTAINER
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 27 September 1990

  • Application: NDA050646
  • Marketing authorisation holder: GLAXOSMITHKLINE
  • Local brand name: CEPTAZ
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA — authorised 9 November 1992

  • Application: ANDA062662
  • Marketing authorisation holder: HOSPIRA
  • Indication: Manufacturing (CMC)
  • Status: approved

Read official source →

FDA — authorised 28 November 2005

  • Application: ANDA064032
  • Marketing authorisation holder: HOSPIRA
  • Indication: Labeling
  • Status: approved

Read official source →

FDA — authorised 26 January 2017

  • Application: NDA206494
  • Marketing authorisation holder: ABBVIE
  • Indication: Efficacy
  • Status: approved

Read official source →

FDA

  • Application: ANDA063322
  • Marketing authorisation holder: GLAXOSMITHKLINE
  • Local brand name: PENTACEF
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Application: ANDA064006
  • Marketing authorisation holder: GLAXOSMITHKLINE
  • Local brand name: PENTACEF
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Application: ANDA064008
  • Marketing authorisation holder: GLAXOSMITHKLINE
  • Local brand name: PENTACEF
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

Fortaz in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in United States

Frequently asked questions

Is Fortaz approved in United States?

Yes. FDA authorised it on 19 July 1985; FDA authorised it on 20 November 1985; FDA authorised it on 20 November 1985.

Who is the marketing authorisation holder for Fortaz in United States?

PAI HOLDINGS PHARM holds the US marketing authorisation.